Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugene S Kandel

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Cell Cycle (Georgetown, Tex.)|May 28, 2009
NFkappaB inhibition and more: a side-by-side comparison of the inhibitors of IKK and proteasomeEugene S Kandel
Oncotarget|July 28, 2012
Mutations in circulating mitochondrial DNA: Cassandra of oral cancer?Eugene S Kandel
Molecular Cell|December 31, 2002
Template switching by RNA polymerase II in vivo. Evidence and implications from a retroviral systemEugene S Kandel, Evgeny Nudler
Oncotarget|August 8, 2012
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenesRuchi Singhal, Eugene S Kandel
Biomolecular Engineering|February 10, 2006
RNA interference in cancerAndrei L Gartel, Eugene S Kandel
Seminars in Cancer Biology|February 26, 2008
miRNAs: Little known mediators of oncogenesisAndrei L Gartel, Eugene S Kandel
Plos One|September 5, 2008
A natural human retrovirus efficiently complements vectors based on murine leukemia virusBeihua Dong, Robert H Silverman, Eugene S Kandel
Cells|October 13, 2023
PAK1 and Therapy Resistance in MelanomaJulia V Kichina, Alexei Maslov, Eugene S Kandel
Cell Cycle (Georgetown, Tex.)|February 7, 2019
The role of PAK1 in the sensitivity of kidney epithelial cells to ischemia-like conditionsEvan R Zynda, Mitchell H Maloy, Eugene S Kandel
Oncotarget|June 7, 2011
Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifactJiawen Yang, Partho Battacharya, Ruchi Singhal, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Cell Cycle (Georgetown, Tex.)|May 28, 2009
NFkappaB inhibition and more: a side-by-side comparison of the inhibitors of IKK and proteasomeEugene S Kandel
Oncotarget|July 28, 2012
Mutations in circulating mitochondrial DNA: Cassandra of oral cancer?Eugene S Kandel
Molecular Cell|December 31, 2002
Template switching by RNA polymerase II in vivo. Evidence and implications from a retroviral systemEugene S Kandel, Evgeny Nudler
Oncotarget|August 8, 2012
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenesRuchi Singhal, Eugene S Kandel
Biomolecular Engineering|February 10, 2006
RNA interference in cancerAndrei L Gartel, Eugene S Kandel
Seminars in Cancer Biology|February 26, 2008
miRNAs: Little known mediators of oncogenesisAndrei L Gartel, Eugene S Kandel
Plos One|September 5, 2008
A natural human retrovirus efficiently complements vectors based on murine leukemia virusBeihua Dong, Robert H Silverman, Eugene S Kandel
Cells|October 13, 2023
PAK1 and Therapy Resistance in MelanomaJulia V Kichina, Alexei Maslov, Eugene S Kandel
Cell Cycle (Georgetown, Tex.)|February 7, 2019
The role of PAK1 in the sensitivity of kidney epithelial cells to ischemia-like conditionsEvan R Zynda, Mitchell H Maloy, Eugene S Kandel
Oncotarget|June 7, 2011
Xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer cells likely represents a laboratory artifactJiawen Yang, Partho Battacharya, Ruchi Singhal, et al.
Pageof 5